Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

Journal of the American College of Cardiology

Volumn 54, Issue 22, 2009, Pages 2023-2031

  Haywood, L Julian ^a   Ford, Charles E ^b   Crow, Richard S ^c   Davis, Barry R ^b   Massie, Barry M ^d   Einhorn, Paula T ^e   Williard, Angela ^f  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f TULANE UNIVERSITY   (United States)

Author keywords

amlodipine; atrial fibrillation; chlorthalidone; clinical trial; doxazosin; hypertension; lisinopril; pravastatin

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHLORTALIDONE; DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LISINOPRIL; PRAVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CLINICAL TRIAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK FACTOR; STATISTICAL ANALYSIS; STROKE;

ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; COMORBIDITY; DOXAZOSIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INCIDENCE; KAPLAN-MEIER ESTIMATE; MYOCARDIAL INFARCTION; PRAVASTATIN; PROGNOSIS; SMOKING;

EID: 71849109250     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.08.020     Document Type: Article

References (35)

1. Moe G.K., and Abildskov J.A. Atrial fibrillation as self-sustaining arrhythmia independent of focal discharge. Am Heart J 58 (1959) 59-70
2. Chen P.S., Athill C.A., Wu T.J., et al. Mechanisms of atrial fibrillation and flutter and implications for management. Am J Cardiol 84 (1999) 125R-130R
3. Benjamin E.J., Chen P.S., Bild D.E., et al. Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop. Circulation 119 (2009) 606-618
4. Prystowsky E.N. Perspectives and controversies in atrial fibrillation. Am J Cardiol 82 (1998) 3I-6I
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
6. Benjamin E.T., Levy D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. JAMA 271 (1994) 840-844
7. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation. The Framingham Heart Study. Circulation 110 (2004) 1042-1046
8. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults. National implications of rhythm management and stroke prevention: the Anticoagulation and Risk Factor in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001) 2370-2375
9. Wattigney W.A., Mensah G.A., and Croft J.B. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 155 (2002) 819-826
10. Davis B.R., Cutler J.A., Gordon D.J., et al., ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9 (1996) 342-360
11. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42 (2003) 239-246
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 288 (2002) 2981-2997
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major events in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 288 (2002) 2998-7
14. Davis B.R., Cutler J.A., Furberg C.D., et al., ALLHAT Collaborative Research Group. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: Further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med 137 (2002) 313-320
15. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
16. Freeston B., Beevers D.G., and Lip G.Y.H. The rennin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?. J Hum Hypertens 18 (2004) 461-465
17. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
18. Dunnett C.W. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc 50 (1955) 1096-1121
19. Wright Jr. J.T., Cushman W.C., Davis B.R., et al., ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience. Control Clin Trials 22 (2001) 659-673
20. Pressel S., Davis B.R., Louis G.T., et al., ALLHAT Research Group. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials 22 (2001) 674-686
21. The fifth report of the Joint National Committee on Detection, Evaluation, and treatment of High Blood Pressure (JNC V). Arch Intern Med 153 (1993) 154-183
22. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
23. Grimm R.H., Margolis K.L., Papademetriou V., et al., ALLHAT Collaborative Research Group. Baseline characteristics of the 42,448 high risk hypertensive enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 37 (2001) 19-27
24. Klein J.P., and Moeschberger M.L. Survival Analysis: Techniques for Censored and Truncated Regression (1997), Springer-Verlag, New York, NY
25. Stevens L.A., Coresh J., Greene T., et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
26. Borzecki A.M., Bridgers D.K., Liebschutz J.M., et al. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc 100 (2008) 237-245
27. Soliman E.Z., and Goff Jr. D.C. The paradox of racial distribution of atrial fibrillation (letter to the editor). J Natl Med Assoc 100 (2008) 447-448
28. Ruo B., Capra A.M., Jensvold N.G., and Go A.S. Racial variation in the prevalence of atrial fibrillation among patients with heart failure. The Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol 43 (2004) 429-435
29. Wright J.T., Dunn J.K., Cutler J.A., et al., ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 293 (2005) 1595-1608
30. Aksnes T.A., Flaa A., Strand A., and Kjeldsen S.E. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J Hypertens 25 (2007) 15-21
31. Schmieder R.E., Kjeldsen S.E., Julius S., et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 26 (2008) 403-411
32. Duchame A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 152 (2006) 66-92
33. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 (2005) 548-557
34. Pellegrini C.N., Vittinghoff E., Lin F., et al. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 95 (2009) 704-708
35. Fauchier L., Pierre B., de Labriolle A., et al. Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 51 (2008) 828-835